ClinicalTrials.gg
CompletedNCT06508320Updated Oct 8, 2026Results posted

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

A Phase 2 interventional study of mRNA-1083 in Influenza and SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 17 sites in 2 countries. Open to participants aged 50 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2, Interventional, and Prevention

Updated Oct 8, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
931
Allocation
Randomized
Ages
50 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Influenza, Human by Moderna, Inc. — 2 open to participants now, 3 under way, 1 of them phase 3. Influenza, Human · Moderna, Inc..

Enrollment
11th of 23
931 · median 885
Started
2024
with 2 others
Phase 2
4 of 23
none open now
Registered
17th of 23
by date

Among the 23 studies in Influenza, Human by Moderna, Inc., this one is the 11th largest by enrollment, is one of 3 that started in 2024, is one of 4 in phase 2, and was the 17th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 23 studies in Influenza, Human by Moderna, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 50 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Influenza, Human by Moderna, Inc., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to \<65 years of age.

Read the detailed description

The study will be comprised of 2 parts, Parts 1 and 2. In Part 1, participants will be randomized into 4 study groups (Lots A, B, C, and D). Upon completion of Part 1, participants will be randomized into 2 study groups (Lots A and E) in Part 2.

03

Conditions studied

  • Influenza
  • SARS-CoV-2

Browse trials for

Keywords

  • Influenza
  • SARS-CoV-2
  • mRNA-1083
04

Who can participate

Ages eligible
50 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Investigator assessment that the participant understands and is willing and physically able to comply with protocol-mandated follow-up, including all procedures.
  2. Participants of nonchildbearing potential may be enrolled in the study.
  3. Participants who could become pregnant: negative pregnancy test, adequate or has abstained from all activities that could result in pregnancy.
  4. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
  5. Have received an influenza vaccine in the previous season (since September 2023 for Part 1, since Sep 2024 for Part 2).

Exclusion criteria

Exclusion Criteria:

  1. Reported diagnosis or condition that is associated with increased risk of severe influenza disease or complications, including individuals with chronic medical conditions.
  2. Reported history of congenital or acquired immunodeficiency, condition, asplenia, or recurrent severe infections.
  3. History of anaphylaxis or severe reaction requiring medical intervention after receipt of any of the following: mRNA vaccine or therapeutic; components of an mRNA vaccine or therapeutic; influenza vaccine; or components of an influenza vaccine, including egg protein.
  4. Received at ≥10 milligrams (mg)/day of prednisone or equivalent for >14 days in total within 90 days prior to Day 1 or is anticipating the need for corticosteroids at any time during the study.
  5. Received systemic immunosuppressive treatment, including long-acting biological therapies that affect immune responses (e.g., infliximab), within 180 days prior to Day 1 or plans to do so during the study.
  6. Received or plans to receive any vaccine authorized or approved by a local health agency within 28 days prior to Day 1 or plans to do so within 28 days post study injection.
  7. Received a licensed seasonal influenza vaccine within 150 days prior to Day 1.
  8. Received a licensed/authorized SARS-CoV-2 vaccine within 90 days prior to Day 1.
  9. Received any influenza vaccine, investigational coronavirus disease 2019 (COVID-19) vaccine, or investigational combination vaccine for influenza and COVID-19 within 12 months prior to Day 1. Participants from mRNA-1083-P201 Part 1 will also be excluded from Part 2.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
931 participants (actual)

Study arms

  • Experimental
    Part 1 Group 1 - mRNA-1083 Lot A

    Participants will receive mRNA-1083 Lot A as a single injection on Day 1 in Part 1.

    Biological: mRNA-1083

  • Experimental
    Part 1 Group 2 - mRNA-1083 Lot B

    Participants will receive mRNA-1083 Lot B as a single injection on Day 1 in Part 1.

    Biological: mRNA-1083

  • Experimental
    Part 1 Group 3 - mRNA-1083 Lot C

    Participants will receive mRNA-1083 Lot C as a single injection on Day 1 in Part 1.

    Biological: mRNA-1083

  • Experimental
    Part 1 Group 4 - mRNA-1083 Lot D

    Participants will receive mRNA-1083 Lot D as a single injection on Day 1 in Part 1.

    Biological: mRNA-1083

  • Experimental
    Part 2 Group 5 - mRNA-1083 Lot A

    Participants will receive mRNA-1083 Lot A as a single injection on Day 1 in Part 2.

    Biological: mRNA-1083

  • Experimental
    Part 2 Group 6 - mRNA-1083 Lot E

    Participants will receive mRNA-1083 Lot E as a single injection on Day 1 in Part 2.

    Biological: mRNA-1083

Interventions

  • BiologicalmRNA-1083

    IM injection in a deltoid muscle.

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B Strains

    The GMT has been measured by (Hemagglutination Inhibition) HAI assay based on ANCOVA Model. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The log-transformed antibody levels are analyzed using an Analysis of Covariance model with intervention group as the fixed variable, log transformed baseline antibody values as a fixed covariate. The model based GMT, and its corresponding 95% CI are obtained by transforming the least square mean estimate and its CI back to the original scale for presentation.

    Time frame: Day 29

  2. Geometric Mean Titer (GMT) of Neutralizing Antibody for SARS-CoV-2

    The GMT has been measured by Pseudovirus Neutralization (PsVNA) assay based on ANCOVA Model. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The log-transformed antibody levels are analyzed using an Analysis of Covariance model with intervention group as the fixed variable, log transformed baseline antibody values as a fixed covariate. The model based GMT, and its corresponding 95% CI are obtained by transforming the least square mean estimate and its CI back to the original scale for presentation.

    Time frame: Day 29

  3. Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

    Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills.

    Time frame: From the day of study injection through 6 subsequent days (Up to 7 days)

  4. Number of Participants With Unsolicited Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence, temporally associated with the use of study intervention, whether or not considered related to study intervention. Any solicited local or systemic adverse reaction that met SAE criteria was to be considered as AE.

    Time frame: From the day of study injection through 27 subsequent days (Up to 28 days)

  5. Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study Discontinuation

    A MAAE was an AE that led to an unscheduled visit to a healthcare practitioner. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: From Day 1 to End of Study (Up to 6 Months)

Secondary outcomes

  1. Geometric Mean Fold Rise (GMFR) of Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B Strains

    The anti-HA antibody values have been measured by (Hemagglutination Inhibition) HAI assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The GMFR 95% CI at Day 29 (relative to Day 1) was calculated based on the t-distribution of the log-transformed values and then back transformed to the original scale for presentation.

    Time frame: Day 29

  2. Geometric Mean Fold Rise (GMT) of Neutralizing Antibody for SARS-CoV-2

    The neutralizing antibody values have been measured by Pseudovirus Neutralization (PsVNA) assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The GMFR 95% CI at Day 29 (relative to Day 1) was calculated based on the t-distribution of the log-transformed values and then back transformed to the original scale for presentation.

    Time frame: Day 29

  3. Percentage of Participants With Seroconversion in Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B Strains

    Seroconversion of antibodies for an influenza strain is defined as a post-vaccination anti-HA antibody value ≥1:40 if baseline is \<1:10 or a ≥4-fold rise in post-vaccination value if baseline is ≥1:10. The anti-HA antibody values have been measured by (Hemagglutination Inhibition) HAI assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ.

    Time frame: Day 29

  4. Percentage of Participants With Seroresponse in Neutralizing Antibody for SARS-CoV-2

    Seroresponse of SARS-CoV-2 antibodies is defined as a post-vaccination neutralizing antibody value ≥4×LLOQ if baseline is \<LLOQ, or a ≥4-fold rise in post-vaccination value if baseline is ≥LLOQ. The neutralizing antibody values have been measured by Pseudovirus Neutralization (PsVNA) assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ.

    Time frame: Day 29

07

Results

Posted Oct 8, 2026

Participant flow

Part 1
Participant flow — Part 1
MilestonePart 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot E
Started15315515515400
Received study intervention15315515315400
Completed14514715214500
Not completed883900
Withdrew: Lost to follow-up651700
Withdrew: Randomized by mistake001000
Withdrew: Withdrawal by subject131100
Withdrew: Other reasons100100
Part 2
Participant flow — Part 2
MilestonePart 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot E
Started0000158156
Received study drug injection0000158156
Completed0000147141
Not completed00001115
Withdrew: Lost to follow-up000068
Withdrew: Withdrawal by subject000046
Withdrew: Other reasons000011

Outcome measures

PrimaryGeometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B Strains

The GMT has been measured by (Hemagglutination Inhibition) HAI assay based on ANCOVA Model. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The log-transformed antibody levels are analyzed using an Analysis of Covariance model with intervention group as the fixed variable, log transformed baseline antibody values as a fixed covariate. The model based GMT, and its corresponding 95% CI are obtained by transforming the least square mean estimate and its CI back to the original scale for presentation.

Time frame:
Day 29
Reported as:
Geometric mean · Titer
Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B Strains
TiterPart 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot E
Influenza A/H1N1268.4 (235.8 to 305.5)272.8 (239.5 to 310.9)280.5 (246.7 to 318.9)269.0 (236.7 to 305.8)148.9 (132.3 to 167.6)119.1 (105.6 to 134.3)
Influenza A/H3N2207.0 (176.2 to 243.1)212.8 (180.9 to 250.5)217.3 (185.2 to 255.0)179.1 (152.7 to 210.1)94.3 (82.4 to 107.9)100.0 (87.2 to 114.6)
Influenza B/Victoria-lineage254.1 (216.5 to 298.3)268.8 (228.6 to 316.1)283.4 (241.7 to 332.2)241.6 (206.2 to 283.2)100.7 (86.9 to 116.8)91.7 (79.0 to 106.5)
Influenza B/Yamagata-lineage98.6 (86.6 to 112.3)118.5 (104.0 to 135.1)105.2 (92.5 to 119.7)100.1 (88.0 to 113.8)40.4 (36.0 to 45.4)40.2 (35.7 to 45.3)
PrimaryGeometric Mean Titer (GMT) of Neutralizing Antibody for SARS-CoV-2

The GMT has been measured by Pseudovirus Neutralization (PsVNA) assay based on ANCOVA Model. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The log-transformed antibody levels are analyzed using an Analysis of Covariance model with intervention group as the fixed variable, log transformed baseline antibody values as a fixed covariate. The model based GMT, and its corresponding 95% CI are obtained by transforming the least square mean estimate and its CI back to the original scale for presentation.

Time frame:
Day 29
Reported as:
Geometric mean · Titer
Geometric Mean Titer (GMT) of Neutralizing Antibody for SARS-CoV-2
TiterPart 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot E
Geometric Mean Titer (GMT) of Neutralizing Antibody for SARS-CoV-23735.0 (3177.7 to 4390.0)3633.5 (3086.4 to 4277.6)4083.0 (3478.6 to 4792.3)3316.2 (2826.9 to 3890.3)3940.5 (3342.4 to 4645.7)3587.9 (3035.0 to 4241.6)
PrimaryNumber of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills.

Time frame:
From the day of study injection through 6 subsequent days (Up to 7 days)
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
ParticipantsPart 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot E
Any Solicited ARs1281221211209999
Solicited Local ARs1171111131089081
Solicited Systemic ARs10810698998084
PrimaryNumber of Participants With Unsolicited Adverse Events (AEs)

An AE was defined as any untoward medical occurrence, temporally associated with the use of study intervention, whether or not considered related to study intervention. Any solicited local or systemic adverse reaction that met SAE criteria was to be considered as AE.

Time frame:
From the day of study injection through 27 subsequent days (Up to 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events (AEs)
ParticipantsPart 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot E
Number of Participants With Unsolicited Adverse Events (AEs)1313131165
PrimaryNumber of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study Discontinuation

A MAAE was an AE that led to an unscheduled visit to a healthcare practitioner. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
From Day 1 to End of Study (Up to 6 Months)
Reported as:
Count of participants · Participants
Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study Discontinuation
ParticipantsPart 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot E
MAAEs1916161877
AESIs101020
SAEs112121
AEs leading to study discontinuation000000
SecondaryGeometric Mean Fold Rise (GMFR) of Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B Strains

The anti-HA antibody values have been measured by (Hemagglutination Inhibition) HAI assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The GMFR 95% CI at Day 29 (relative to Day 1) was calculated based on the t-distribution of the log-transformed values and then back transformed to the original scale for presentation.

Time frame:
Day 29
Reported as:
Geometric mean · Ratio
Geometric Mean Fold Rise (GMFR) of Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B Strains
RatioPart 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot E
Influenza A/H1N12.35 (2.06 to 2.67)2.42 (2.12 to 2.77)2.58 (2.25 to 2.96)2.51 (2.17 to 2.91)2.53 (2.20 to 2.92)2.16 (1.93 to 2.42)
Influenza A/H3N24.02 (3.39 to 4.77)4.32 (3.61 to 5.16)4.21 (3.57 to 4.97)3.61 (3.08 to 4.23)2.55 (2.26 to 2.87)2.70 (2.31 to 3.17)
Influenza B/Victoria-lineage3.79 (3.19 to 4.51)3.98 (3.26 to 4.87)4.47 (3.69 to 5.42)3.97 (3.36 to 4.7)2.77 (2.36 to 3.26)2.64 (2.26 to 3.09)
Influenza B/Yamagata-lineage2.34 (2.10 to 2.61)2.86 (2.45 to 3.35)2.55 (2.19 to 2.97)2.50 (2.20 to 2.85)1.94 (1.73 to 2.16)2.03 (1.77 to 2.34)
SecondaryGeometric Mean Fold Rise (GMT) of Neutralizing Antibody for SARS-CoV-2

The neutralizing antibody values have been measured by Pseudovirus Neutralization (PsVNA) assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ. The GMFR 95% CI at Day 29 (relative to Day 1) was calculated based on the t-distribution of the log-transformed values and then back transformed to the original scale for presentation.

Time frame:
Day 29
Reported as:
Geometric mean · Ratio
Geometric Mean Fold Rise (GMT) of Neutralizing Antibody for SARS-CoV-2
RatioPart 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot E
Geometric Mean Fold Rise (GMT) of Neutralizing Antibody for SARS-CoV-29.45 (7.40 to 12.06)11.95 (9.10 to 15.69)12.05 (9.44 to 15.37)9.67 (7.82 to 11.96)12.22 (9.48 to 15.74)10.58 (8.23 to 13.61)
SecondaryPercentage of Participants With Seroconversion in Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B Strains

Seroconversion of antibodies for an influenza strain is defined as a post-vaccination anti-HA antibody value ≥1:40 if baseline is \<1:10 or a ≥4-fold rise in post-vaccination value if baseline is ≥1:10. The anti-HA antibody values have been measured by (Hemagglutination Inhibition) HAI assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ.

Time frame:
Day 29
Reported as:
Number · Percent of participants
Percentage of Participants With Seroconversion in Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B Strains
Percent of participantsPart 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot E
Influenza A/H1N129.3 (22.0 to 37.3)31.9 (24.4 to 40.2)38.9 (31.1 to 47.2)32.7 (25.2 to 40.8)30.5 (23.4 to 38.4)22.8 (16.3 to 30.4)
Influenza A/H3N251.7 (43.3 to 60.0)49.3 (40.9 to 57.8)57.7 (49.4 to 65.8)47.3 (39.1 to 55.6)35.1 (27.6 to 43.2)34.2 (26.7 to 42.4)
Influenza B/Victoria-lineage46.9 (38.7 to 55.3)47.2 (38.9 to 55.7)56.4 (48.0 to 64.5)52.0 (43.7 to 60.2)40.3 (32.3 to 48.6)34.9 (27.2 to 43.3)
Influenza B/Yamagata-lineage28.6 (21.4 to 36.6)38.9 (30.9 to 47.4)31.5 (24.2 to 39.7)31.3 (24.0 to 39.4)17.5 (11.9 to 24.5)25.5 (18.7 to 33.3)
SecondaryPercentage of Participants With Seroresponse in Neutralizing Antibody for SARS-CoV-2

Seroresponse of SARS-CoV-2 antibodies is defined as a post-vaccination neutralizing antibody value ≥4×LLOQ if baseline is \<LLOQ, or a ≥4-fold rise in post-vaccination value if baseline is ≥LLOQ. The neutralizing antibody values have been measured by Pseudovirus Neutralization (PsVNA) assay. Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are converted to the ULOQ.

Time frame:
Day 29
Reported as:
Number · Percent of participants
Percentage of Participants With Seroresponse in Neutralizing Antibody for SARS-CoV-2
Percent of participantsPart 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot E
Percentage of Participants With Seroresponse in Neutralizing Antibody for SARS-CoV-272.1 (64.1 to 79.2)72.9 (64.9 to 80.0)73.8 (66.0 to 80.7)73.3 (65.5 to 80.2)71.4 (63.6 to 78.4)69.8 (61.7 to 77.0)

Adverse events

Collected over All-cause mortality was collected throughout the entire period of the study. SAEs were collected from the time of informed consent through Day 181/EOS. Other adverse events were collected from the time of injection through 28 days after injection, unless they met the criteria for SAEs, AESIs, MAAEs or AEs leading to discontinuation (which were collected from day 1 through Day 181/EOS).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 Group 1 - mRNA-1083 Lot A0/153 (0%)1/153 (0.7%)0/153 (0%)
Part 1 Group 2 - mRNA-1083 Lot B0/155 (0%)1/155 (0.6%)0/155 (0%)
Part 1 Group 3 - mRNA-1083 Lot C0/155 (0%)2/153 (1.3%)0/153 (0%)
Part 1 Group 4 - mRNA-1083 Lot D0/154 (0%)1/154 (0.6%)0/154 (0%)
Part 2 Group 5 - mRNA-1083 Lot A0/158 (0%)2/158 (1.3%)0/158 (0%)
Part 2 Group 6 - mRNA-1083 Lot E0/156 (0%)1/156 (0.6%)0/156 (0%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPart 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot E
DiverticulitisInfections and infestations1/1530/1550/1530/1540/1580/156
Tonsil cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1530/1551/1530/1540/1580/156
Alcohol withdrawal syndromePsychiatric disorders0/1530/1551/1530/1540/1580/156
Post procedural infectionInfections and infestations0/1530/1550/1531/1540/1580/156
OrchitisInfections and infestations0/1531/1550/1530/1540/1580/156
West Nile viral infectionInfections and infestations0/1531/1550/1530/1540/1580/156
Foot fractureInjury, poisoning and procedural complications0/1530/1550/1530/1540/1581/156
UrosepsisInfections and infestations0/1530/1550/1530/1541/1580/156
Status epilepticusNervous system disorders0/1530/1550/1530/1541/1580/156
Atrial flutterCardiac disorders0/1530/1550/1530/1541/1580/156

Baseline characteristics

The Randomization Set included all participants who were randomized in the study, regardless of the participant's treatment status in the study.

Age, Continuous
Age, Continuous(Years)Part 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot ETotal
Mean58.2 ± 4.2757.1 ± 4.2456.7 ± 4.4457.3 ± 4.4157.2 ± 4.1956.8 ± 4.2557.2 ± 4.32
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot ETotal
Female9096941099689574
Male635961456267357
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot ETotal
Hispanic or Latino74767776117116536
Not Hispanic or Latino787978753840388
Unknown or Not Reported1003307
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1 Group 1 - mRNA-1083 Lot APart 1 Group 2 - mRNA-1083 Lot BPart 1 Group 3 - mRNA-1083 Lot CPart 1 Group 4 - mRNA-1083 Lot DPart 2 Group 5 - mRNA-1083 Lot APart 2 Group 6 - mRNA-1083 Lot ETotal
White125120117122123109716
Black or African American222831273245185
Asian21320210
American Indian or Alaska Native0000101
Native Hawaiian or Other Pacific Islander0000000
Multiple1101003
Other1212006
Unknown/Not Reported23302010
08

Study locations

17 sites
  • Indago Research & Health Center, Inc.
    Hialeah, Florida 33012, United States
  • Cenexel RCA
    Hollywood, Florida 33024, United States
  • Suncoast Research Group, LLC DBA Flourish Research
    Miami, Florida 33135, United States
  • Cenexel IRA
    Decatur, Georgia 30030, United States
  • DM Clinical Research - River Forest
    River Forest, Illinois 60305, United States
  • JCCT
    Lenexa, Kansas 66219, United States
  • Hassman Research Institute - Berlin - CenExel - PPDS
    Marlton, New Jersey 80530, United States
  • DM Clinical Research - Philadelphia
    Philadelphia, Pennsylvania 19107, United States
  • DM Clinical Research - Cyfair Clinical Research Center - PPDS
    Houston, Texas 77065-5685, United States
  • Clinical Trials of Texas, LLC DBA Flourish Research
    San Antonio, Texas 78229, United States
  • DM Clinical Research - Sugarland
    Sugar Land, Texas 77478, United States
  • DM Clinical Research - Tomball MDC
    Tomball, Texas 77375, United States
  • Centricity Research
    Toronto, Ontario M4G 3E8, Canada
  • Centricity Research
    Toronto, Ontario M9W 4L6, Canada
  • Centricity Research
    Pointe-Claire, Quebec H9R4S3, Canada
  • Diex Recherche Sherbrooke Inc.
    Sherbrooke, Quebec J1L 0H8, Canada
  • Diex Recherche Québec Inc.
    Québec, G1V 4T3, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Sep 2025, 14 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 14 months is above that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2024
First posted
Jul 18, 2024
StartActual
Jul 15, 2024
Primary completionActual
Sep 25, 2025
CompletionActual
Sep 25, 2025
Results first posted
Oct 8, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 8, 2026
Enrollment
932→931
Oct 8, 2026
Interventions
Arm changed Part 1 Group 1: mRNA-1083 Lot A→Part 1 Group 1 - mRNA-1083 Lot A; Part 1 Group 2: mRNA-1083 Lot B→Part 1 Group 2 - mRNA-1083 Lot B; Part 1 Group 3: mRNA-1083 Lot C→Part 1 Group 3 - mRNA-1083 Lot C; Part 1 Group 4: mRNA-1083 Lot D→Part 1 Group 4 - mRNA-1083 Lot D; Part 2 Group 5: mRNA-1083 Lot A→Part 2 Group 5 - mRNA-1083 Lot A; Part 2 Group 6: mRNA-1083 Lot E→Part 2 Group 6 - mRNA-1083 Lot E
Oct 8, 2026
Primary outcomes
3 edited, 2 added, 5 removed
What changed in the outcomes
  • EditedNumber of Participants withWith Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Up to Day 7 (7 days after vaccination) → From the day of study injection through 6 subsequent days (Up to 7 days)
  • EditedNumber of Participants withWith Unsolicited Adverse Events (AEs)Time frame: Up to Day 28 (28 days after vaccination) → From the day of study injection through 27 subsequent days (Up to 28 days)
  • EditedNumber of Participants withWith Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study DiscontinuationTime frame: Up to Day 181 → From Day 1 to End of Study (Up to 6 Months)
  • AddedGeometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B StrainsTime frame: Day 29
  • AddedGeometric Mean Titer (GMT) of Neutralizing Antibody for SARS-CoV-2Time frame: Day 29
  • RemovedGeometric Mean Value of Antibodies at Day 29, as Measured by Hemagglutinin Inhibition (HAI) Assay for InfluenzaTime frame: Day 29
  • RemovedGeometric Mean Value of Antibodies at Day 29, as Measured by Pseudovirus Neutralization Assay (PsVNA) for SARS-CoV-2Time frame: Day 29
  • RemovedNumber of Participants with Medically Attended Adverse Events (MAAEs)Time frame: Up to Day 181
  • RemovedNumber of Participants with Serious Adverse Events (SAEs)Time frame: Up to Day 181
  • RemovedNumber of Participants with AEs Leading to Discontinuation from Study ParticipationTime frame: Up to Day 181
Oct 8, 2026
Documents
Secondary outcomes
1 edited, 3 added, 3 removed
What changed in the outcomes
  • EditedPercentage of Participants With Seroresponse Rate (SRR) in Neutralizing Antibody (nAb) Values at Day 29, as Measured by PsVNA for SARS-CoV-2Time frame: Day 29
  • AddedGeometric Mean Fold Rise (GMFR) of Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B StrainsTime frame: Day 29
  • AddedGeometric Mean Fold Rise (GMT) of Neutralizing Antibody for SARS-CoV-2Time frame: Day 29
  • AddedPercentage of Participants With Seroconversion in Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B StrainsTime frame: Day 29
  • RemovedGeometric Mean Fold Rise (GMFR) of Antibodies at Day 29 Relative to Day 1, as Measured by HAI Assay for InfluenzaTime frame: Day 1, Day 29
  • RemovedGMFR of Antibodies at Day 29 Relative to Day 1, as Measured by PsVNA for SARS-CoV-2Time frame: Day 1, Day 29
  • RemovedSeroconversion Rate (SCR) in Anti-hemagglutinin (HA) Antibody Values at Day 29, as Measured by HAI Assay for InfluenzaTime frame: Day 29
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Results posted
    Enrollment 932→931
    Primary outcomes 3 edited, 2 added, 5 removed
    What changed in the outcomes
    • EditedNumber of Participants withWith Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Up to Day 7 (7 days after vaccination) → From the day of study injection through 6 subsequent days (Up to 7 days)
    • EditedNumber of Participants withWith Unsolicited Adverse Events (AEs)Time frame: Up to Day 28 (28 days after vaccination) → From the day of study injection through 27 subsequent days (Up to 28 days)
    • EditedNumber of Participants withWith Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study DiscontinuationTime frame: Up to Day 181 → From Day 1 to End of Study (Up to 6 Months)
    • AddedGeometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B StrainsTime frame: Day 29
    • AddedGeometric Mean Titer (GMT) of Neutralizing Antibody for SARS-CoV-2Time frame: Day 29
    • RemovedGeometric Mean Value of Antibodies at Day 29, as Measured by Hemagglutinin Inhibition (HAI) Assay for InfluenzaTime frame: Day 29
    • RemovedGeometric Mean Value of Antibodies at Day 29, as Measured by Pseudovirus Neutralization Assay (PsVNA) for SARS-CoV-2Time frame: Day 29
    • RemovedNumber of Participants with Medically Attended Adverse Events (MAAEs)Time frame: Up to Day 181
    • RemovedNumber of Participants with Serious Adverse Events (SAEs)Time frame: Up to Day 181
    • RemovedNumber of Participants with AEs Leading to Discontinuation from Study ParticipationTime frame: Up to Day 181
    Secondary outcomes 1 edited, 3 added, 3 removed
    What changed in the outcomes
    • EditedPercentage of Participants With Seroresponse Rate (SRR) in Neutralizing Antibody (nAb) Values at Day 29, as Measured by PsVNA for SARS-CoV-2Time frame: Day 29
    • AddedGeometric Mean Fold Rise (GMFR) of Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B StrainsTime frame: Day 29
    • AddedGeometric Mean Fold Rise (GMT) of Neutralizing Antibody for SARS-CoV-2Time frame: Day 29
    • AddedPercentage of Participants With Seroconversion in Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B StrainsTime frame: Day 29
    • RemovedGeometric Mean Fold Rise (GMFR) of Antibodies at Day 29 Relative to Day 1, as Measured by HAI Assay for InfluenzaTime frame: Day 1, Day 29
    • RemovedGMFR of Antibodies at Day 29 Relative to Day 1, as Measured by PsVNA for SARS-CoV-2Time frame: Day 1, Day 29
    • RemovedSeroconversion Rate (SCR) in Anti-hemagglutinin (HA) Antibody Values at Day 29, as Measured by HAI Assay for InfluenzaTime frame: Day 29
    Interventions Arm changed Part 1 Group 1: mRNA-1083 Lot A→Part 1 Group 1 - mRNA-1083 Lot A; Part 1 Group 2: mRNA-1083 Lot B→Part 1 Group 2 - mRNA-1083 Lot B; Part 1 Group 3: mRNA-1083 Lot C→Part 1 Group 3 - mRNA-1083 Lot C; Part 1 Group 4: mRNA-1083 Lot D→Part 1 Group 4 - mRNA-1083 Lot D; Part 2 Group 5: mRNA-1083 Lot A→Part 2 Group 5 - mRNA-1083 Lot A; Part 2 Group 6: mRNA-1083 Lot E→Part 2 Group 6 - mRNA-1083 Lot E
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06508320
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Jul 18, 2024
Start date
Jul 15, 2024
Primary completion
Sep 25, 2025
Completion
Sep 25, 2025
Results posted
Oct 8, 2026
Last update
Oct 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MRNA-1083

Start the discussion